This study aimed to review the improvement of artificial joint materials to search ideal materials for artificial joint. The developing process of metal artificial joint, high polymer artificial joint, ceramic-made artificial joint and compound material artificial joint was introduced and the material surface processing was explored. Selection of materials for artificial joint is determined by many factors. Each material has the specific benefits and drawbacks, so we can improve their performance by certain processing. Although there are many studies about materials for artificial joint, no ideal material is identified. To develop the materials for artificial joint with high mechanical strength, good biocompatibility, strong abradability and long-term service life is the focus in future bone tissue engineering.

Objective To evaluate the curative effect of transurethral electrosection for the treatment of bladder neck sclerosis in senile patients. Methods Clinical data of 36 aged patients with bladder neck sclerosis treated by transurethral electrosection in this hospital from February to September, 2000, were reviewed. The curative effect was evaluated according to the improvement of dysuria, residual urine volume (RUV) and Qmax before and after the surgery. Results Follow-up for 3～18 months (mean, 7 months) in 30 patients showed an effective rate of 86.7% (26/30) and no severe complications. Conclusions Transurethral electrosection is an effective alternative for bladder neck sclerosis in senile men.

Background and purpose:The clear-cell cancer ovarian cancer have worse prognosis than the other ovarian cancer.The patient's survival rate of the clear-cell ovarian cancer has been analyzed in this article in order to study the effect of the treatment with CAPcytoxan(CTX),cisplatinum(DDP),epiadriamycin(E-ADM)plus mitomycin(MMC).Methods:33 cases(group A)with clear-cell ovarian cancer between Jan.1th 1999 and Dec.31th 1999 were compared to 37 cases(B group)with other pathological ovarian cancer.All cases underwent the tumor reductive surgery and been capable of remain the residual tumor size less than 1 cm.Patients in the two groups all underwent CAP based chemotherapy,and patients in group A with additional MMC chemotherapy at the same time.Group A had been compared with the clear-cell ovarian cancer with the CAP protocol(group C,stage Ⅰ/Ⅱ 15 cases,stage Ⅲ/Ⅳ 9 cases).Results:There was significant statistical different value of the CA125 in stage Ⅰ/Ⅱ before operation and no significant statistical difference for stage Ⅲ/Ⅳ between the two groups.There were significant decrease in the CA125 value for the stage Ⅰ/Ⅱ and no significant decrease for stage Ⅲ/Ⅳ between two groups after three and six courses chemotherapy.There were 11(33.33%)cases developed with endometriosis and 7(21.21%)with deep venous thrombosis(DVT),however the DVT had no direct correlation to the survival rate.The average survival time for stages Ⅰ/Ⅱ in group A and B was(38.3?2.4),and(38.3?2.7)months,compared to(20?3)and(34?4)months in stage Ⅲ/Ⅳ,respectively.There was no significant statistical difference(P=0.471)in four-year survival rate between groups A and B with stage Ⅰ/Ⅱ and there was significant statistical difference(P

Purpose:To study the intraperitonal chemotherapy combined with intravenous chemotherapy after surgery for the treatment of ovarian cancer. Methods:The 88 patients of ovarian cancer after cytoreductive surgery were divided into two groups A and B. A group(45 cases) received intraperitonal chemotherapy three times once a week with DDP and 5-FU plus either the MMC or AT-1258, then intravenous chemotherapy, stages Ⅰ/Ⅱ 21 cases(23.86%),stages Ⅲ/Ⅳ 24 cases(27.27%). B groups were given intravenous chemotherapy with CAP protocol once every three weeks,stage Ⅰ/Ⅱ 24 cases(27.27%),stages Ⅲ/Ⅳ 19 cases(21.59%).Results:After three or six courses of chemotherapy there was significant decrease in CA125 both Ⅰ/Ⅱ and Ⅲ/Ⅳ in A and B groups . After three courses of chemotherapy there were 34 cases((38.64%))of A groups and 19 cases(21.59%)of the B groups with CA12535 u/ml(35 cases) who were given three courses of chemotherapy after entire treatment. A and B groups in the Ⅰ/Ⅱ stages showed average survival time (35.05?0.54),(32.38?1.19) months,and in the Ⅲ/Ⅳ stages showed average survival time (31.33?1.41),(28.26?1.88) months.There was no significance (P=0.156) with three year survival rate between A and B groups in the Ⅰ/Ⅱ stages with Log Rank test. There was no significance (P=0.08) in three-year survival rate between A and B groups in the Ⅲ/Ⅳ stages with Log Rank test. There was significance in three-year survival rate between A and B with intraperitonal fluid.Conclusions:The intraperitonal chemotherapy combined with intravenous chemotherapy after surgery for the treatment of ovarian cancer could marketly decrease CA125 than intravenous chemotherapy after three or six courses. Three-year survival ratewas significantly different between CA125 35 u/ml(35 cases) when they were given three courses of chemotherapy after entire treatment. Although the intraperitonal chemotherapy after surgery for the treatment of ovarian cancer had no significant difference between A and B groups in Ⅰ/Ⅱ and Ⅲ/Ⅳ stages with three-year survival rate , it appears longer survival time . There is significant difference with three-year survival between A and B with intraperitonal fluid. The intraperitional chemotherapy combined with intravenous chemotherapy after surgery can be used for the ovarian cancer with intraperitonal fluid and metastases.

ObjectiveTo investigate the risk factors of benign prostate hyperplasia (BPH).Methods A total of 738 male subjects were assigned to the non-BPH + non-metabolic syndrome (MS)group (group A),BPH + non-MS group (group B),MS + non-BPH group (group C),and BPH + MS group ( group D).Body mass index(BMI),systolic blood pressure ( SBP),diastolic blood pressure ( DBP),fasting blood glucose ( FBG ),total cholesterol ( TC ),triglyceride ( TG ),low-density lipoprotein cholesterol ( LDL-C),high-density lipoprotein cholesterol ( HDL-C ),glycosylated alanine aminotransferase ( ALT ),serum creatinine,hemoglobin (HbAlc),and serum uric acid (UA) were measured.Results In comparison with group A,age,BMI,SBP,DBP,TG,TC,LDL-C and HbAlc of group B were significantly increased,although HDL-C was significantly reduced.Age,BMI,SBP,DBP,TG,TC,LDL-C,UA and HbAlc of group D were significantly higher than those of group C,while HDL-C was relatively lower.In multivariate logistic regression analysis,＞ 60 years [odds ratio (OR) =4.432,95％ confidence interval (CI) 1.331 to 14.759],overweight/obese ( OR =228.165,95％ CI 21.932 to 2373.724 ),hypertension ( OR =33.350,95％ CI 10.221 to 108.824),higher FBG ( OR =131.669,95％ CI 21.033 to 824.279 ),and higher TG ( OR =53.500,95％ CI 11.547 to 247.889 ) were independent risk factors of BPH with MS.Conclusion Our data suggest a close relationship between BPH and MS.Elderly,overweight/obesity,and higher blood pressure,TC or FBG might be the risk factors of BPH and MS.

Objective To investigate the prevalences of benign prostatic hyperplasia (BPH) and metabolic syndrome (MS) and to analyze the risk factors for benign prostatic hyperplasia and metabolic syndrome in the elderly.Methods A total of 490 elderly men undergoing health examination in our hospital from January 2010 to December 2010 were divided into BPH and MS group (n=246),MS group (n=55),BPH group (n=44),non-BPHandnon-MSgroup (control,n =145).Body height,body weight,body mass index (BMI),systolic blood pressure (SBP),diastolic blood pressure (DBP) were detected.Fasting blood glucose (FBG),serum total cholesterol (TC),triglyceride (TG),low-density lipoprotein cholesterol (LDL-C),high-density lipoprotein cholesterol (HDL-C),alanine a minotransferase (ALT),creatinine (CRE),glycated hemoglobin (HbA1c),serum uric acid (UA) and other indicators were measured.Results The prevalences of BPH and MS were increased with age (x 2=810.71,732.18,both P＜0.05).Age,BMI,blood pressure,the levels of FBG,TG,TC,LDL-C,UA and HbA1c were significantly higher in BPH and MS group than in control group (all P＜0.05),while HDL-C concentration was significantly lower in group BPH and MS than in control group (P＜0.05).Age was significantly higher in group BPH and MS than in MS group (P＜0.05).Age,BMI,blood pressure,levels of FBG and TG were significantly higher in group BPH and MS than in BPH group (all P＜0.05),while HDL-C concentration was significantly lower in group BPH and MS than in group C (P＜0.05).Multivariate logistic regression analysis showed that age＞70 years,obesity,hypertension,high FBG,high TG,lower HDL-C were independent risk factors for BPH and MS (OR:2.947,4.470,4.790,11.589,27.850,0.391,respectively,all P＜ 0.05).Conclusions The prevalences of BPH and MS are gradually increased with ageing in elderly men.Age ＞ 70 years,obesity,hypertension,high fasting glucose,hypertriglyceridemia and lower HDL-C are the risk factors for BPH and MS.

Background and purpose:The greastest diameter of cervical cancer with stage Ⅰ_(b2) disease was more than 4 cm in diameter. surgery as the fi rst priority was diffi cult in these patients, bleeding was the most frequent adverse effect. This article studied the effect of the cervical cancer with stage Ⅰ_(b2) disease underwent neoadjuvant chemotherapy with gemcitabin plus cisplatinum(DDP). Methods:23 cases (A groups) stage Ⅰ_(b2) cervical cancer were treated with gemcitabin 1.5 g/m2 iv infusion at d1, plus cisplatinum(DDP) 20 mg/m2 iv infusion at d1-3. The interval between the two cycles was two weeks.19 cases (B groups) were treated with cisplatinum(DDP) 20 mg/m2 iv infusion at d1-3,plus VCR 1.5 g/m2 iv infusion at d1, and BLM 10 mg/m2 im at d1-3, The interval between the two cycles was three weeks. The assessment for clinical effect and side effect were conducted for the patients with completion of at least two cycles of chemotherapy. Results:42 cases were enrolled in this trial. There was signifi cant(P=0.004) difference between the two groups with the shrinkage of the greatest diameter after neoadjuvant chemotherapy. The main toxicities were myelosuppression. There was signifi cant (P

Objective To observe the curative effect and side effect ofdifferent dosage of flurbiprofen applied in refractory renal colic cases.Methods Two hundred refractory renal cohc cases were randomly divided into group A and group B,each group was 100 cases.Group A were apphed 100 mg flurbiprofen injection,group B were applied 50 mg flurbiprofen injection.Observed the time of the colic pain reheved,the curative effect and side effect Results The total effective rate of group A and group Bwere 99%(99/100)and 91%(911100)respectively,there was significant difference between two groups(P<0.05).In the time to relieve of group A and group B were(8.3±5.7)min and(13.2±9.1)min respectively,there Was significant difference between two groups(P<0.05).Analgesia continuous time of group A and group B were(19.3 ±3.2)h and(14.5 4±5.1)h respectively,there was no significant difference between two groups(P>0.05).And side effect was no significant difference between two groups.Conclusion The curative effect of 100mg flurbiprofen injection applied to the refractory renal colic cases is very outstanding,the time to relieve is very shod but side effect dose not increase.

Objective To evaluate the safety and clinical efficacy of finasteride in treating patients with benign prostatic hyperplasia (BPH) during a 14-year period in a hospital.Methods Forty-one patients with BPH receiving finasteride 5 mg daily for the treatment from December 1994 to Febrary 2009 were included in the study. The base line and the end of study data of nocturia, prostate volume, serum creatine, complete blood count and serum prostatic specific antigen (PSA) were recorded. The acute urinary retention, surgical treatment and drug adverse reaction (prostate cancer or breast cancer) during the observation periods were recorded as well.ResultsAll the 41 cases took finasteride regularly for long-term medical therapy of BPH. At the end of this study, the average age of patients was (87.9±5.4) years old and the average duration of treatment was (141.1±27.1) months. The numbers of nocturia were 1.8±1.5 and 3.2±1.3 pre- and post- treatment, respectively (t= -4.52,P<0. 05). Before and at the end of the study, the prostate volumes were (44.9±26.6) ml and (42.8±31.3) ml, respectively(t=0. 33,P>0.05). Stratified study showed that, compared with the baseline data, the prostate volume was increased by 17.3 ％ in patients with prostate volume <25 ml(t= -0. 88 ,P>0. 05) ; the prostate volume was decreased by 17.2％ in patients with prostate volume of 25-40 ml(t=2.59,P<0.05); the prostate volumes were (63.3±28. 9) ml and (62.6±36.5) ml pre- and post-treatment in patients with prostate volume > 40 ml, and there was no significant change(t= 0.07, P>0. 05). Before and after the treatment, the serum creatine levels were (96.8±18. 6) mol/L and (86.45±32. 3) mol/L, respectively(t= 1.79, P>0. 05) ; the white blood cell counts were (6.4±1.5) × 109 L and (6.0±1.7) ×109 L, respectively (t= 1.13,P>0. 05) ; and the PSA levels were (1.2±2.0) μg/L and (1.4±1.7) μg/L, respectively (t=-0. 49,P>0. 05). Three cases (7.3％) occurred acute urinary retention. There was no prostate cancer and breast cancer case, and no new adverse event occurred during long-time use of finasteride. Conclusions This retrospective study has demonstrated that the clinical progress of BPH can be controlled effectively by long-term administration of finasteride.

Objective To study the treatment of highly active antiretroviral therapy (HAART) in patients with HIV infection and AIDS and the patients′ survival time after HAART treatment. Methods Three thousand and one hundred cases of HIV infection and AIDS patients received HAART in 12 months by monthly flow cytometry instrument MultiSET absolute counting method detecting the CD4+T cell levels, bDNA method (detection range 1.60 log ~ 6.10 log RNA copies/mL) detecting serum HIV-1 viral load under rigorous clinical observation. Results Twelve months after treatment, the CD4+T cell count increased an average of 430 × 106/L (P < 0.01). Eight months after treatment, all viral loads reached their measurable levels (below 1.70 log copies/mL) by decreasing 45 log copies/mL on average. Conclusion HIV/AIDS patients showed treatment extremely significant possitive responses to highly active antiretroviral therapy. The patients′ survival rate after treatment has greatly improved compare to that in previous literature.